Intuitive Surgical (ISRG) insider buying and selling
Every Table I transaction reported by directors and officers of S&P 500 companies on SEC Form 4 filings (2 business days to file): each row labeled with its official transaction code, nothing filtered out beforehand.
Open-market purchases (code P) are the rare signal, in green; sales (code S) are common and often pre-scheduled (10b5-1). Table II (derivatives) is not included: its prices are exercise prices, not market values. Guide: insider buying.
| Date | Ticker | Insider | Role | Shares | Price | Amount | % of stake | Type / filing |
|---|
Download these transactions as CSV No account, no sign-up. The data is public: it comes from SEC Form 4 filings.
Intuitive Surgical, Inc. (ISRG) insider buying and selling: no purchases, 71 sales
169 Form 4 Table I transactions filed with the SEC by Intuitive Surgical, Inc. insiders between 2025-09-02 and 2026-10-13 (15-month history): 0 open-market purchases and 71 sales, plus 98 transactions under other Form 4 codes, broken down one by one below. The largest open-market trade is a sale of $17.3M by Guthart Gary S on 2025-10-24.
Intuitive Surgical insider buying and selling over the last 12 months
Between Oct 21, 2025 and Oct 20, 2026, Intuitive Surgical insiders filed 68 sales worth $93.3M on the open market, and no purchases.
The biggest seller was Guthart Gary S (Director): $48.8M in 4 sales, out of 12 different sellers.
The largest trade of the period was a sale of $17.3M on Oct 24, 2025, by Guthart Gary S (Executive Chair of the Board o), under a 10b5-1 plan. Form 4 on sec.gov (0001280628-25-000004).
All 68 sales carry the 10b5-1 plan flag on the Form 4: scheduled months ahead.
The last three months show 19 sales, against 15 in the three before. The latest sale from Sep 15, 2026.
Against its sector (Healthcare, 59 companies with an insider page on this site), over the same dates the median is 9 sales and 0 purchases on the open market. Intuitive Surgical has more sales than 58 of the other 58, ranks 9 of 59 by net dollars sold, and 19 of the 59 have at least one purchase.
The 20 most important trades
With no open-market purchases, the table starts with ISRG's sales, largest first. The full history is in the tool above, already searched.
See all 169 ISRG trades in the full history →
| Trade date | Filed | Insider | Role | Amount | Code | Filing |
|---|---|---|---|---|---|---|
| 2025-10-24 | 2025-10-27 | Guthart Gary S | Executive Chair of the Board o | $17.3M | S — Open-market sale (scheduled 10b5-1) Indirect holding, through: Trust FBO Daughter; Trust FBO Son 4 Form 4 footnotesF1 The transaction took place in accordance with a Trading Plan that complies with SEC Rule 10b5-1 and expires on April 28, 2026. F2 The price reported in Column 4 is a weighted average sale price. These shares were sold in multiple transactions at prices ranging from $541.76 to $550.16 as follows: 800 shares sold at $541.76 to $542.59; 1,000 shares sold at $542.89 to $543.22; 2,563 shares sold at $544 to $545; 1,600 shares sold at $545.33 to $546.29; 2,770 shares sold at $546.34 to $547.19; 7,383 shares sold at $547.35 to $548.31; 9,068 shares sold at $548.36 to $549.35; and 3,616 shares sold at $549.485 to $550.16. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. F3 The price reported in Column 4 is a weighted average sale price. These shares were sold in multiple transactions at prices ranging from $542.74 to $548.48 as follows: 100 shares sold at $542.74; 205 shares sold at $543.97 to $544.45; 250 shares sold at $545.06 to $545.94; 200 shares sold at $546.46 to $546.75; and 645 shares sold at $547.49 to $548.48. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. F4 The price reported in Column 4 is a weighted average sale price. These shares were sold in multiple transactions at prices ranging from $542.16 to $548.45 as follows: 190 shares sold at $542.16 to $542.98; 150 shares sold at $543.79 to $544.30; 190 shares sold at $545.00 to $545.33; 292 shares sold at $546.34 to $547.20; and 578 shares sold at $547.51 to $548.45. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. | SEC |
| 2026-01-27 | 2026-01-28 | Guthart Gary S | Director | $14.5M | S — Open-market sale (scheduled 10b5-1) Indirect holding, through: Trust FBO Daughter; Trust FBO Son 4 Form 4 footnotesF1 The transaction took place in accordance with a Trading Plan that complies with SEC Rule 10b5-1 and expires on April 28, 2026. F2 The price reported in Column 4 is a weighted average sale price. These shares were sold in multiple transactions at prices ranging from $525.51 to $534.00 as follows: 2,500 shares sold at $525.51 to $525.71; 280 shares sold at $526.94 to $527.41; 2,252 shares sold at $528.23 to $529.18; 9,860 shares sold at $529.27 to $530.27; 3,475 shares sold at $530.29 to $531.22; 1,589 shares sold at $531.37 to $532.24; 3,704 shares sold at $532.53 to $533.41; and 840 shares sold at $533.82 to $534.00. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. F3 The price reported in Column 4 is a weighted average sale price. These shares were sold in multiple transactions at prices ranging from $529.77 to $534.00 as follows: 520 shares sold at $529.77 to $530.61; 298 shares sold at $530.98 to $531.87; 302 shares sold at $532.05 to $532.61; and 280 shares sold at $533.82 to $534.00. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. F4 The price reported in Column 4 is a weighted average sale price. These shares were sold in multiple transactions at prices ranging from $529.77 to $534.00 as follows: 520 shares sold at $529.77 to $530.61; 360 shares sold at $530.98 to $531.86; 240 shares sold at $532.05 to $532.61; and 280 shares sold at $533.82 to $534.00. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. | SEC |
| 2025-08-29 | 2025-09-02 | Guthart Gary S | Executive Chair of the Board o | $13.9M | S — Open-market sale (scheduled 10b5-1)2 Form 4 footnotesF1 The transaction took place in accordance with a Trading Plan that complies with SEC Rule 10b5-1 and expires on April 28, 2026. F2 The price reported in Column 4 is a weighted average sale price. These shares were sold in multiple transactions at prices ranging from $469.04 to $475.40 as follows: 5,200 shares sold at $469.04 to $470.03; 3,440 shares sold at $470.21 to $471.17; 4,400 shares sold at $471.38 to $472.38; 6,194 shares sold at $472.64 to $473.60; 7,921 shares sold at $473.79 to $474.72; and 2,205 shares sold at $475.00 to $475.40. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. | SEC |
| 2025-10-24 | 2025-10-27 | Rosa David J. | Chief Executive Officer (CEO) | $13.4M | S — Open-market sale (scheduled 10b5-1)2 Form 4 footnotesF1 The transaction took place in accordance with a Trading Plan that complies with SEC Rule 10b5-1 and expires on June 11, 2026. F2 The price reported in Column 4 is a weighted average sale price. These shares were sold in multiple transactions at prices ranging from $542.16 to $550.21 as follows: 1,075 shares sold at $542.16 to $543.10; 1,000 shares sold at $543.23 to $544.22; 1,830 shares sold at $544.30 to $545.06; 1,300 shares sold at $545.33 to $546.15; 2,346 shares sold at $546.34 to $547.30; 6,919 shares sold at $547.37 to $548.37; 7,257 shares sold at $548.40 to $549.40; and 2,773 shares sold at $549.42 to $550.21. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. | SEC |
| 2025-12-01 | 2025-12-02 | Guthart Gary S | Executive Chair of the Board o | $13.0M | S — Open-market sale (scheduled 10b5-1)2 Form 4 footnotesF1 The transaction took place in accordance with a Trading Plan that complies with SEC Rule 10b5-1 and expires on April 28, 2026. F2 The price reported in Column 4 is a weighted average sale price. These shares were sold in multiple transactions at prices ranging from $568.62 to $573.54 as follows: 5,550 shares sold at $568.62 to $569.62; 6,304 shares sold at $569.64 to $570.63; 2,285 shares sold at $570.66 to $571.61; 5,528 shares sold at $571.70 to $572.70; 3,139 shares sold at $572.72 to $573.54. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. | SEC |
| 2025-11-12 | 2025-11-13 | Charlton Henry L | EVP & Chief Commercial and Mkt | $8.0M | S — Open-market sale (scheduled 10b5-1)Form 4 footnoteF1 The transaction took place in accordance with a Trading Plan that complies with SEC Rule 10b5-1 and expires on June 1, 2026. | SEC |
| 2025-10-28 | 2025-10-29 | Curet Myriam | EVP & Chief Medical Officer | $4.1M | S — Open-market sale (scheduled 10b5-1)2 Form 4 footnotesF1 The transaction took place in accordance with a Trading Plan that complies with SEC Rule 10b5-1 and expires on July 29, 2026. F2 The price reported in Column 4 is a weighted average sale price. These shares were sold in multiple transactions at prices ranging from $545.57 to $551.71 as follows: 1,173 shares sold at $545.57 to $546.54; 2,460 shares sold at $546.69 to $547.63; 314 shares sold at $547.72 to $548.68; 2,610 shares sold at $549.26 to $550.21; 1,000 shares sold at $550.39 to $551.04; 5 shares sold at $551.71. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. | SEC |
| 2026-08-11 | 2026-08-12 | Guthart Gary S | Director | $4.0M | S — Open-market sale (scheduled 10b5-1) Indirect holding, through: by Trust Form 4 footnoteF1 The transaction took place in accordance with a Trading Plan that complies with SEC Rule 10b5-1 and expires on June 15, 2027. | SEC |
| 2025-12-12 | 2025-12-15 | Brosius Mark | SVP & Chief Mfg and Supply Cha | $2.5M | S — Open-market sale (scheduled 10b5-1)Form 4 footnoteF1 The transaction took place in accordance with a Trading Plan that complies with SEC Rule 10b5-1 and expires on February 14, 2027. | SEC |
| 2026-06-01 | 2026-06-02 | Jeddi Iman | SVP & GM da Vinci Platforms & | $2.4M | S — Open-market sale (scheduled 10b5-1)Form 4 footnoteF1 The transaction took place in accordance with a Trading Plan that complies with SEC Rule 10b5-1 and expires on June 5, 2026. | SEC |
| 2026-03-03 | 2026-03-03 | Curet Myriam | EVP & Chief Medical Officer | $2.3M | S — Open-market sale (scheduled 10b5-1) Indirect holding, through: by Trust Form 4 footnoteF1 The transaction took place in accordance with a Trading Plan that complies with SEC Rule 10b5-1 and expires on July 29, 2026. | SEC |
| 2025-11-10 | 2025-11-12 | Miller Brian Edward | EVP & Chief Digital Officer | $2.0M | S — Open-market sale (scheduled 10b5-1)Form 4 footnoteF1 These shares were sold in accordance with a Trading Plan that complies with SEC Rule 10b5-1 and expires on December 10, 2025. | SEC |
| 2025-10-24 | 2025-10-27 | Barratt Craig H | Director | $1.2M | S — Open-market sale (scheduled 10b5-1)Form 4 footnoteF1 The transaction took place in accordance with a Trading Plan that complies with SEC Rule 10b5-1 and expires on April 29, 2026. | SEC |
| 2026-03-04 | 2026-03-05 | Brosius Mark | SVP & Chief Mfg and Supply Cha | $1.2M | S — Open-market sale (scheduled 10b5-1)2 Form 4 footnotesF1 The transaction took place in accordance with a Trading Plan that complies with SEC Rule 10b5-1 and expires on February 14, 2027. F3 The price reported in Column 4 is a weighted average sale price. These shares were sold in multiple transactions at prices ranging from $495.19 to $500.00 as follows: 648 shares sold at $495.19 and 1,714 shares sold at $500.00. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. | SEC |
| 2026-02-27 | 2026-03-02 | Curet Myriam | EVP & Chief Medical Officer | $1.2M | S — Open-market sale (scheduled 10b5-1) Indirect holding, through: by Trust Form 4 footnoteF1 The transaction took place in accordance with a Trading Plan that complies with SEC Rule 10b5-1 and expires on July 29, 2026. | SEC |
| 2025-11-05 | 2025-11-06 | Widman Fredrik | VP Corporate Controller | $1.1M | S — Open-market sale (scheduled 10b5-1)Form 4 footnoteF1 The transaction took place in accordance with a Trading Plan that complies with SEC Rule 10b5-1 and expires on May 21, 2026. | SEC |
| 2025-11-12 | 2025-11-13 | Barratt Craig H | Director | $435k | S — Open-market sale (scheduled 10b5-1)Form 4 footnoteF1 The transaction took place in accordance with a Trading Plan that complies with SEC Rule 10b5-1 and expires on April 29, 2026. | SEC |
| 2026-09-15 | 2026-09-16 | Widman Fredrik | VP Corporate Controller | $408k | S — Open-market sale (scheduled 10b5-1)Form 4 footnoteF1 The transaction took place in accordance with a Trading Plan that complies with SEC Rule 10b5-1 and expires on September 15, 2027. | SEC |
| 2026-03-05 | 2026-03-05 | Brosius Mark | SVP & Chief Mfg and Supply Cha | $321k | S — Open-market sale (scheduled 10b5-1)Form 4 footnoteF1 The transaction took place in accordance with a Trading Plan that complies with SEC Rule 10b5-1 and expires on February 14, 2027. | SEC |
| 2026-03-06 | 2026-03-10 | Brosius Mark | SVP & Chief Mfg and Supply Cha | $318k | S — Open-market sale (scheduled 10b5-1)Form 4 footnoteF1 The transaction took place in accordance with a Trading Plan that complies with SEC Rule 10b5-1 and expires on February 14, 2027. | SEC |
The period balance: money in, money out
In the Form 4 filings submitted between Sep 2, 2025 and Oct 13, 2026 there is not one open-market purchase of Intuitive Surgical, Inc.: 71 sales worth $107.4M and zero dollars bought.
Only codes P and S count, where an insider puts in or takes out their own money. A selling balance like Intuitive Surgical, Inc.'s is the norm in the S&P 500, where much of the pay comes as stock. It is not a recommendation to buy or sell: it is what was filed.
Every transaction, code by code
| Code | What it means | Trades | Reported amount |
|---|---|---|---|
| S | Open-market sale | 71 | $107.4M |
| M | Option exercise | 63 | $23.1M |
| F | Tax withholding (shares surrendered for taxes) | 32 | $33.4M |
| G | Gift | 2 | $0 |
| J | Other transaction (explained in the filing) | 1 | $0 |
| Total | Everything filed in the period | 169 | $163.9M |
43 of the 169 rows carry no usable amount on the Form 4: they count as trades and add $0. The code labels come from the SEC index.
Who has traded
Over the 15 months of history, 20 distinct people or entities have filed Intuitive Surgical, Inc. transactions: none bought on the open market and 12 sold. Counted by CIK, the fixed number the SEC gives each filer, and not by name, which each filer types their own way.
Of the 12 who sold on the open market (71 sales in all), the three biggest sellers account for $84.5M of the $107.4M: 79% of the money in three people.
| Filer | Role | Transactions | Bought (count) | Sold (count) | Last filed |
|---|---|---|---|---|---|
| Guthart Gary S | Director | 15 | — | $62.7M (5) | 2026-08-12 |
| Rosa David J. | Chief Executive Officer (CEO) | 11 | — | $13.4M (1) | 2026-07-13 |
| Curet Myriam | EVP & Chief Medical Officer | 28 | — | $8.4M (13) | 2026-03-11 |
| Charlton Henry L | EVP & Chief Commercial and Mkt | 8 | — | $8.0M (1) | 2026-03-02 |
| Brosius Mark | EVP & Chief Mfg and Supply Cha | 39 | — | $5.7M (32) | 2026-09-11 |
| Jeddi Iman | SVP & GM da Vinci Platforms & | 8 | — | $2.4M (1) | 2026-06-02 |
| Miller Brian Edward | EVP & Chief Digital Officer | 2 | — | $2.0M (1) | 2025-11-12 |
| Widman Fredrik | VP Corporate Controller | 13 | — | $1.8M (5) | 2026-09-16 |
Shown here are the 8 who moved the most money, out of 20. The rest are in the full history, one link above. The name links to all their trades, in any company. "Transactions" counts any code; the money, open market only. Role: from their latest filing.
Month by month
By the month the trade was executed, not the month it was filed; months with no trades show zero. The busiest month was Mar 2026: 0 purchases and 9 sales, worth $4.9M. 1 of the 15 months have none.
| Month | Purchases | Amount | Sales | Amount |
|---|---|---|---|---|
| Aug 2025 | 0 | $0 | 1 | $13.9M |
| Sep 2025 | 0 | $0 | 2 | $306k |
| Oct 2025 | 0 | $0 | 5 | $36.1M |
| Nov 2025 | 0 | $0 | 5 | $11.6M |
| Dec 2025 | 0 | $0 | 6 | $16.1M |
| Jan 2026 | 0 | $0 | 3 | $14.7M |
| Feb 2026 | 0 | $0 | 6 | $1.7M |
| Mar 2026 | 0 | $0 | 9 | $4.9M |
| Apr 2026 | 0 | $0 | 2 | $292k |
| May 2026 | 0 | $0 | 6 | $218k |
| Jun 2026 | 0 | $0 | 7 | $2.6M |
| Jul 2026 | 0 | $0 | 5 | $49k |
| Aug 2026 | 0 | $0 | 9 | $4.5M |
| Sep 2026 | 0 | $0 | 5 | $450k |
| Oct 2026 | 0 | $0 | 0 | $0 |
The last month may be partial: a Form 4 is filed up to two business days later. The table does not say whether the pattern is good or bad; it says when it happened.
Intuitive Surgical, Inc. (ISRG) analysis page →
Other Healthcare companies with insider trades
All 500 are listed in the section index →
Which insiders are buying their own company stock →
How to read this data
20 of the 20 sales in the table are flagged as scheduled (10b5-1 plan): signed months ahead and executed automatically, so they say nothing about what the insider thinks today. Intuitive Surgical has no open-market purchase (code P) in the history, the most common case in the S&P 500: insiders are already paid in stock. The latest filing is from Oct 13, 2026, and a Form 4 arrives up to two business days after the trade.
20 of the 20 rows in the table carry footnotes from the Form 4 itself, folded into the code column and copied verbatim; a row with no footnote means the filing has none.
Guide: Insider buying · all guides
What is behind these trades
The concepts on this page, explained from scratch in the Academy. Free, no account.
- What the efficiency hypothesis says and what it does NOT sayIf an insider's purchase is public and anyone can read it, is there any information left in it? That is the exact question that brings people here.
- Who really moves the market: the types of investorWho sits on the other side of each order, and where a company's own insiders fit among them.
- Supply, demand and price: why it rises and falls constantlyHow a piece of news ends up inside the price, and why the reaction to a filed sale is rarely the one you would expect.
Source: SEC EDGAR Form 4. This is a list of public facts, not financial advice or a recommendation to buy or sell.